CORMEDIX INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
CORMEDIX INC. (CRMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 471.56 thousand shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2023-03-30
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2021-06-30 was 6.53K shares.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2021-03-31 was 21.88K shares, a 24.04% decline year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2020-12-31 was 5.00K shares, a 90.62% decline year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2020-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 471.56K shares, a 0.41% decline from fiscal 2021.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 473.52K shares, a 1300.95% increase from fiscal 2020.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2020 was 33.80K shares, a 60.69% decline from fiscal 2019.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2019 was 85.99K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | 471.56K shares 10-K · filed 2023-03-30 | ||||
| 2021-12-31 | 473.52K shares 10-K · filed 2022-03-29 | ||||
| 2021-06-30 | 6.53K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 28.41K shares 10-Q · filed 2021-08-12 | 33.41K shares derived: sum of 3 quarters · filed 2021-08-12 | 33.41K shares derived: sum of 4 quarters · filed 2021-08-12 | |
| 2021-03-31 | 21.88K shares 10-Q · filed 2021-05-13 | 26.88K shares derived: sum of 2 quarters · filed 2021-05-13 | 26.88K shares derived: sum of 3 quarters · filed 2021-05-13 | 26.88K shares derived: sum of 4 quarters · filed 2021-05-13 | |
| 2020-12-31 | 5.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | 5.00K shares derived: sum of 2 quarters · filed 2021-03-30 | 5.00K shares derived: sum of 3 quarters · filed 2021-03-30 | 33.80K shares 10-K · filed 2021-03-30 | |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-05 | 28.80K shares 10-Q · filed 2020-11-05 | 82.10K shares derived: sum of 4 quarters · filed 2020-11-05 | |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 28.80K shares 10-Q · filed 2020-08-10 | 82.10K shares derived: sum of 3 quarters · filed 2020-08-10 | 93.03K shares derived: sum of 4 quarters · filed 2020-08-10 | |
| 2020-03-31 | 28.80K shares 10-Q · filed 2020-05-11 | 82.10K shares derived: sum of 2 quarters · filed 2020-05-11 | 93.03K shares derived: sum of 3 quarters · filed 2020-05-11 | 93.03K shares derived: sum of 4 quarters · filed 2020-05-11 | |
| 2019-12-31 | 53.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | 64.23K shares derived: sum of 2 quarters · filed 2020-03-16 | 64.23K shares derived: sum of 3 quarters · filed 2020-03-16 | 85.99K shares 10-K · filed 2020-03-16 | |
| 2019-09-30 | 10.93K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | 10.94K shares derived: sum of 2 quarters · filed 2019-11-14 | 32.69K shares 10-Q · filed 2019-11-14 | ||
| 2019-06-30 | 3.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | 21.76K shares 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | 21.75K shares 10-Q · filed 2019-05-13 | ||||
| 2018-09-30 | 1.54K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | 1.54K shares derived: sum of 2 quarters · filed 2018-11-14 | 50.72K shares 10-Q · filed 2018-11-14 | ||
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | 49.18K shares 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | 49.18K shares 10-Q · filed 2018-05-15 | ||||
| 2017-09-30 | 313.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | 433.12K shares derived: sum of 2 quarters · filed 2017-11-09 | 433.12K shares 10-Q · filed 2017-11-09 | ||
| 2017-06-30 | 120.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | 120.00K shares 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-10 | ||||
| 2012-12-31 | -263.05K shares 10-K/A · filed 2014-03-04 | ||||
| 2012-04-30 | 135.00K shares 10-Q/A · filed 2013-03-27 | ||||
| 2011-12-31 | -1.31M shares 10-K/A · filed 2014-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |